Towards virtual laboratory for optimizing cardiac rhythm

项目总结 MedicoSolv Ablation Technologies，Inc.已经开发出一种基于模拟的 无创预测脑梗塞患者导管消融最佳靶点的方法 关联性室性心动过速。成功完成商业化将带来重大的 室性心动过速消融临床过程中的范式转变，其中准确预测 每个患者心脏的最佳消融目标将通过卡托索夫的方法学来实现 在临床程序之前。在这些预测的指导下，消融的交付将是迅速和准确的， 以最小的病变面积根除所有与梗塞相关的室性心动过速。这将导致一个 显著改善了治疗的有效性和耐受性，以及减少了治疗后 手术并发症。 该项目的目标是完成一项临床试验，以收集支持安全性、有效性和 给索赔贴上标签，最终目标是监管部门批准将该设备推向市场。

PROJECT SUMMARY CardioSolv Ablation Technologies, Inc. has developed and aims to commercialize a simulation-based approach for non-invasive prediction of the optimal targets of catheter ablation in patients with infarct- related ventricular tachycardia. Successful completion of the commercialization will result in a major paradigm shift in the clinical procedure of ventricular tachycardia ablation, where accurate prediction of the optimal targets of ablation in each patient heart will be carried out by CardioSolv’s methodology prior to the clinical procedure. Guided by these predictions, delivery of ablation will be swift and precise, eradicating all infarct-related ventricular tachycardias with minimum lesion sizes. This will result in a dramatic improvement in the efficacy of and tolerance for the therapy, as well as in reduction of post- procedure complications. The aim of this project is to complete a clinical trial to collect data in support of safety, efficacy, and labeling claims, with the ultimate goal of regulatory clearance to market the device.